Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.

PURPOSE: Hu antibodies previously have been associated with longer survival of patients with small-cell lung cancer (SCLC). Voltage-gated calcium channel (VGCC) antibodies play a pathogenic role in Lambert Eaton myasthenic syndrome, which is also associated with SCLC. These antibodies may reduce tum...

Full description

Bibliographic Details
Main Authors: Monstad, SE, Drivsholm, L, Storstein, A, Aarseth, J, Haugen, M, Lang, B, Vincent, A, Vedeler, C
Format: Journal article
Language:English
Published: 2004
_version_ 1797094193830559744
author Monstad, SE
Drivsholm, L
Storstein, A
Aarseth, J
Haugen, M
Lang, B
Vincent, A
Vedeler, C
author_facet Monstad, SE
Drivsholm, L
Storstein, A
Aarseth, J
Haugen, M
Lang, B
Vincent, A
Vedeler, C
author_sort Monstad, SE
collection OXFORD
description PURPOSE: Hu antibodies previously have been associated with longer survival of patients with small-cell lung cancer (SCLC). Voltage-gated calcium channel (VGCC) antibodies play a pathogenic role in Lambert Eaton myasthenic syndrome, which is also associated with SCLC. These antibodies may reduce tumor growth in patients with the neurologic disease, but it is not clear whether they provide prognostic information in those without neurologic symptoms. PATIENTS AND METHODS:Two hundred patients with SCLC (age 39 to 79 years; mean, 62.3 years; 129 males and 71 females) receiving chemotherapy were studied for the presence of Hu and VGCC antibodies. Sera were examined for Hu antibodies by an in vitro transcription-translation-based immunoprecipitation technique and by immunohistochemistry/dot blot. VGCC (P/Q subtype) antibodies were detected by radioimmunoassay. Survival analysis was used to analyze the data. Results Hu antibodies were detected in 51 of 200 patients (25.5%) by in vitro transcription-translation-based immunoprecipitation and in 37 of 200 patients (18.5%) by immunohistochemistry or dot blot, whereas VGCC antibodies were detected in only 10 of 200 patients (5%). The presence of Hu antibodies did not correlate with VGCC antibodies, and there was no association between Hu or VGCC antibodies and the extent of disease or survival. CONCLUSION: Hu and VGCC antibodies are found in a proportion of SCLC patients, irrespective of neurologic symptoms, but their presence does not correlate with the prognosis of the SCLC.
first_indexed 2024-03-07T04:10:40Z
format Journal article
id oxford-uuid:c7b940b9-ea74-4b9b-b0ba-eca50f1eb286
institution University of Oxford
language English
last_indexed 2024-03-07T04:10:40Z
publishDate 2004
record_format dspace
spelling oxford-uuid:c7b940b9-ea74-4b9b-b0ba-eca50f1eb2862022-03-27T06:47:12ZHu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c7b940b9-ea74-4b9b-b0ba-eca50f1eb286EnglishSymplectic Elements at Oxford2004Monstad, SEDrivsholm, LStorstein, AAarseth, JHaugen, MLang, BVincent, AVedeler, CPURPOSE: Hu antibodies previously have been associated with longer survival of patients with small-cell lung cancer (SCLC). Voltage-gated calcium channel (VGCC) antibodies play a pathogenic role in Lambert Eaton myasthenic syndrome, which is also associated with SCLC. These antibodies may reduce tumor growth in patients with the neurologic disease, but it is not clear whether they provide prognostic information in those without neurologic symptoms. PATIENTS AND METHODS:Two hundred patients with SCLC (age 39 to 79 years; mean, 62.3 years; 129 males and 71 females) receiving chemotherapy were studied for the presence of Hu and VGCC antibodies. Sera were examined for Hu antibodies by an in vitro transcription-translation-based immunoprecipitation technique and by immunohistochemistry/dot blot. VGCC (P/Q subtype) antibodies were detected by radioimmunoassay. Survival analysis was used to analyze the data. Results Hu antibodies were detected in 51 of 200 patients (25.5%) by in vitro transcription-translation-based immunoprecipitation and in 37 of 200 patients (18.5%) by immunohistochemistry or dot blot, whereas VGCC antibodies were detected in only 10 of 200 patients (5%). The presence of Hu antibodies did not correlate with VGCC antibodies, and there was no association between Hu or VGCC antibodies and the extent of disease or survival. CONCLUSION: Hu and VGCC antibodies are found in a proportion of SCLC patients, irrespective of neurologic symptoms, but their presence does not correlate with the prognosis of the SCLC.
spellingShingle Monstad, SE
Drivsholm, L
Storstein, A
Aarseth, J
Haugen, M
Lang, B
Vincent, A
Vedeler, C
Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title_full Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title_fullStr Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title_full_unstemmed Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title_short Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
title_sort hu and voltage gated calcium channel vgcc antibodies related to the prognosis of small cell lung cancer
work_keys_str_mv AT monstadse huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT drivsholml huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT storsteina huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT aarsethj huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT haugenm huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT langb huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT vincenta huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer
AT vedelerc huandvoltagegatedcalciumchannelvgccantibodiesrelatedtotheprognosisofsmallcelllungcancer